DANVILLE, CA–(Marketwire – March 8, 2010) –  S3 Investment Company, Inc. (PINKSHEETS: SIVC) today announced that the company’s Redwood Medical subsidiary, which distributes Western medical technologies and products into the China market, is currently working on additional State Food and Drug Administration (SFDA) approvals for the first product it has signed to distribute in China. 

Further information:

Article source

Related posts:

1. S3 Investment Company Announces New Client for Redwood Capital Subsidiary
2. S3 Investment Company Comments on New Redwood Capital Subsidiary Client and Its Potential in China’s Cattle Industry
3. S3 Investment Company Comments on Additional Contracts Valued at Over $57 Million Announced by Redwood Capital Client
4. Sunridge Receives Approval For Its Non-Invasive Glaucoma Treatment In China
5. China Aoxing In-Licenses China Rights for Narcotic Drug Combo